William Blair Has Negative Forecast for Zoetis Q3 Earnings

Key Points

• William Blair has lowered its Q3 2025 earnings per share forecast for Zoetis from $1.64 to $1.60, while maintaining a full-year earnings estimate of $6.07 per share.
• Zoetis' recent quarterly results showed earnings of $1.76 per share, exceeding analysts' expectations of $1.62, with a revenue of $2.46 billion.
• The company will declare a quarterly dividend of $0.50 on December 2nd, reflecting an annualized yield of 1.4% and a payout ratio of 34.42%.

Zoetis Inc. (NYSE:ZTS - Free Report) - Research analysts at William Blair cut their Q3 2025 earnings per share (EPS) estimates for shares of Zoetis in a research report issued to clients and investors on Monday, October 13th. William Blair analyst B. Vazquez now forecasts that the company will post earnings of $1.60 per share for the quarter, down from their prior estimate of $1.64. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. William Blair also issued estimates for Zoetis' Q4 2025 earnings at $1.45 EPS, Q3 2026 earnings at $1.74 EPS and Q4 2026 earnings at $1.59 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.

A number of other brokerages have also recently issued reports on ZTS. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Argus reaffirmed a "buy" rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Zoetis in a research note on Wednesday, October 8th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $196.71.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $143.45 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $63.58 billion, a price-to-earnings ratio of 24.69, a P/E/G ratio of 2.28 and a beta of 0.90. The stock's fifty day moving average price is $148.98 and its two-hundred day moving average price is $154.11. Zoetis has a one year low of $139.34 and a one year high of $196.55.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis's dividend payout ratio is presently 34.42%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ZTS. Lindbrook Capital LLC increased its position in Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after acquiring an additional 65 shares during the period. Scott & Selber Inc. raised its position in Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock worth $1,817,000 after purchasing an additional 67 shares during the last quarter. North Star Asset Management Inc. lifted its holdings in Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company's stock worth $225,000 after buying an additional 67 shares during the period. Secure Asset Management LLC increased its stake in shares of Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock valued at $382,000 after buying an additional 68 shares during the period. Finally, Quotient Wealth Partners LLC raised its position in shares of Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after acquiring an additional 72 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.